SOUTH SAN FRANCISCO, Calif.,
Aug. 22, 2019 /PRNewswire/
-- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA)
today announced that the Company will participate in the following
conferences in September.
- Citi's 14th Annual Biotech Conference on
Wednesday, September 4, 2019, in
Boston, MA. The Company will
conduct one-on-one meetings with institutional investors at this
conference.
- Morgan Stanley's 17th Annual Global Healthcare
Conference on Tuesday, September 10,
2019, at 11:45 a.m. Eastern
Time in New York, NY. The
Company will participate in a fireside chat presentation at the
conference, which will be webcast live and available for replay in
the Investor Relations section of the Portola website (www.portola.com).
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic conditions. The Company's first
two commercialized products are Andexxa® [coagulation
factor Xa (recombinant), inactivated-zhzo], marketed in
Europe as Ondexxya®
(andexanet alfa), and Bevyxxa® (betrixaban). The company
also is advancing cerdulatinib, a SYK/JAK inhibitor being developed
for the treatment of hematologic cancers. Founded in 2003 in
South San Francisco, California,
Portola has operations in
the United States and Europe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-300905577.html
SOURCE Portola Pharmaceuticals, Inc.®